期刊文献+

地特胰岛素治疗2型糖尿病临床观察

下载PDF
导出
摘要 目的观察地特胰岛素治疗2型糖尿病的临床疗效。方法本文选择了自2009年2月—2010年2月我院收治的2型糖尿病患者70例,其中男性19例,女性21例,年龄为60~76岁。所选患者口服药控制均不理想,在原来的服药方案基础上,将其分为两组,观察组与对照组,每组各35例,观察组患者每天睡前接受1次地特胰岛素注射治疗,对照组患者接受甘精胰岛素注射治疗。疗程为12周,观察两组患者在治疗前后的胰岛素用量、糖化血红蛋白(HbA1C)、空腹血糖(FBG)及其达标时间和低血糖发生率等指标。结果两组患者在治疗前后的HbA1C和FBG均有显著降低(P<0.05),但两组比较差异无统计学意义(P>0.05),观察组患者的血糖达标时间、胰岛素用量和低糖发生率比对照组患者少(P<0.05)。结论地特胰岛素对治疗2型糖尿病安全、有效,值得临床推广使用。
作者 赵宇
出处 《中国卫生产业》 2012年第27期95-95,共1页 China Health Industry
  • 相关文献

参考文献4

二级参考文献44

  • 1The Diabetes Control and Complications Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care, 1995,18 : 1415-1427.
  • 2UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998,352: 837 -853.
  • 3Yki-Jarvinen H, Ryysy L, Kauppila M, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1997,82 : 4037-4043.
  • 4DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care, 1988,11 : 567-573.
  • 5Lin X, Taguchi A,Park S, et al. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and dia betes. J Clin Invest,2004,114:908-916.
  • 6Brunner GA, Sendhofer G, Wutte A, et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinol Diabetes, 2000,108 : 100-105.
  • 7Havelund S, Ribel U, Plum A, et al. The mechanism of protraction of insulin detemir, a long acting, acylated analogue of human insulin. Diabetes, 2004,53 : P462.
  • 8Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insu lins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia, 2004,47 : 622-629.
  • 9Raslovd K, Bogoev M, Raz I,et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract, 2004,66:193-201.
  • 10Haak T, Tiengo A, Draeger E,et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab, 2005,7 : 56-64.

共引文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部